Loading clinical trials...
Loading clinical trials...
A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
Conditions
Interventions
AZD0466
Locations
5
United States
Research Site
New Haven, Connecticut, United States
Research Site
Boston, Massachusetts, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Nashville, Tennessee, United States
Research Site
Houston, Texas, United States
Start Date
December 16, 2019
Primary Completion Date
June 18, 2021
Completion Date
June 18, 2021
Last Updated
August 2, 2023
NCT07249528
NCT04570423
NCT00131014
NCT07177937
NCT03050268
NCT06215118
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions